Adaptación Cultural y Validación al español de España del MSTCQ©“Multiple SclerosisTreatment Concerns Questionnaire”.

dc.contributor.authorMunteis Olivas, Elviraca
dc.contributor.authorNavarro Mascarell, Guillermoca
dc.contributor.authorMeca-Lallana, Joséca
dc.contributor.authorMaestre Martínez, Asunciónca
dc.contributor.authorPérez-Sempere, Ángelca
dc.contributor.authorGracia Gil, Juliaca
dc.contributor.authorPato Pato, Antonioca
dc.date.accessioned2017-03-15T07:48:29Z
dc.date.issued2017
dc.description.abstractINTRODUCTION: Although subcutaneos treatments for multiple sclerosis (MS) have been shown to be effective, adverse reactions and pain may adversely affect treatment satisfaction and adherence. This study presents an adapted and validated Spanish version of the Multiple Sclerosis Treatment Concerns Questionnaire© (MSTCQ), which evaluates satisfaction with the injection device (ID) across 4 domains: injection system (A), side effects (B) (flu-like symptoms, reactions, and satisfaction), experience with treatment (C) and benefits (D). METHODS: Two study phases: 1) Cultural adaptation process with input from experts (n=6) and patients (n=30). 2) Validation obtained by means of an observational, cross-sectional, multi-centre study evaluating 143 adult MS patients using an ID. Tools employed: MSTCQ©, Patient-Reported Indices for Multiple Sclerosis (PRIMUS©), and Treatment Satisfaction Questionnaire for Medication (TSQM©). Psychometric properties: Feasibility (percentage of valid cases and floor/ceiling effects); Reliability (Cronbach α) and test-retest correlation (n=41, intraclass correlation coefficient, ICC); and construct validity (factor analysis of domains A and B) and convergent validity (Spearman rank-order correlation for MSTCQ© vs TSQM©). RESULTS: Mean age (SD) was 41.94 (10.47) years, 63% of the group were women, and 88.11% presented relapsing-remitting MS. Mean (SD) EDSS score was 2.68 (1.82) points. MSTCQ© completion was high (0%-2.80% missing data). Internal consistency was high at α=0.89 for the total score (A+B) and α=0.76, 0.89, and 0.92 for domains A, B, and C, respectively. The version demonstrated excellent test-retest reliability for the total (ICC=0.98) and for domains A, B, and C: ICC=0.82, 0.97, and 0.89, respectively. Factor analysis corroborated the internal structure of the original questionnaire. The association between total and domain scores on both the MSTCQ© and the TSQM© was moderately strong (Rho=0.42-0.74) and significant (P<.05 and P<.01). CONCLUSION: The Spanish version of MSTCQ© demonstrates appropriate psychometric properties.ca
dc.description.sponsorshipEl estudio ha sido financiado por Novartis Farmacéutica S.A.
dc.format.mimetypeapplication/pdfca
dc.identifier.citationMuntéis Olivas E, Navarro Mascarell G, Meca Lallana J, Maestre Martínez A, Pérez Sempere Á, Gracia Gil J. et al. Adaptación Cultural y Validación al español de España del MSTCQ©“Multiple SclerosisTreatment Concerns Questionnaire”. Neurologia. 2017 Jan - Feb;32(1):29-39. doi: 10.1016/j.nrl.2014.12.011ca
dc.identifier.doihttp://dx.doi.org/10.1016/j.nrl.2014.12.011
dc.identifier.issn0213-4853
dc.identifier.urihttp://hdl.handle.net/10230/28230
dc.language.isospaca
dc.publisherElsevierca
dc.relation.ispartofNeurologia. 2017 Jan - Feb;32(1):29-39
dc.rights© Elsevier http://dx.doi.org/10.1016/j.nrl.2014.12.011ca
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccessca
dc.subject.otherEsclerosi múltiple -- Tractamentca
dc.subject.otherQüestionarisca
dc.titleAdaptación Cultural y Validación al español de España del MSTCQ©“Multiple SclerosisTreatment Concerns Questionnaire”.ca
dc.typeinfo:eu-repo/semantics/articleca
dc.type.versioninfo:eu-repo/semantics/acceptedVersionca

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
munteis-neu-adap.pdf
Size:
768.24 KB
Format:
Adobe Portable Document Format
Description: